Benzinga | Oct 19, 2021 09:04AM EDT

Applied UV Says Co's Systems Proven To Kill Candida Auris, An Emerging Multi-Drug-Resistant Fungus

Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced today that based on preliminary internal laboratory test results, its Airocide(r) Air Purification System, Applied UV's proprietary airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst, kills the emerging multi-drug resistant fungus, Candida auris ("C. auris"). According to the CDC, "C.auris can cause severe infections and spread easily between hospitalized patients and nursing home residents." For more information about fungal diseases and COVID-19, please click the following link: https://www.cdc.gov/fungal/covid-fungal.html

Additionally, in September of 2021, ResInnova Laboratories, an independent microbiology testing laboratory specializing in antimicrobial technologies, confirmed that the Company's devices kill C. auris from sink handles, achieving a log2 kill in just fifteen minutes of operation. Prior testing on UV devices indicated that 30 to 45 minutes was needed to achieve a log2 kill or higher (99.99% reduction) which is what health care providers consider significant. The results from the Resinnova test demonstrate a reduction in virus destruction time when compared to existing UV devices.

These new recently announced test results from MRIGlobal, and ResInnova Laboratories, both independent, research organizations, confirm that Applied UV's Airocide and Sterilumen air purification and surface disinfection systems kill SARS-CoV-2 (COVID-19 Virus) and C. auris, which will continue to support the Company's global commercialization strategy.

Candida auris is an emerging fungus that presents a serious global health threat. It enters the body through the skin and infects the bloodstream, central nervous system, and multiple internal organs. It has been identified as being multiple drug resistant, and the disease is particularly pernicious in patients with weakened immune systems, and that is why it is so problematic in hospitals as well as long-term care facilities. The Centers for Disease Control and Prevention ("CDC ") currently considers Candidiasis as one of the most significant infectious diseases in the world today. To view the CDC's fact sheet on drug-resistant C. auris, click on the following link: https://www.cdc.gov/drugresistance/pdf/threats-report/candida-auris-508.pdf